We are live on ! Find out more
GALT icon

Galectin Therapeutics

75 hedge funds and large institutions have $22.7M invested in Galectin Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.46% less ownership

Funds ownership: 18.87% → 17.41% (-1.5%)

4% less funds holding

Funds holding: 78 → 75 (-3)

15% less call options, than puts

Call options by funds: $226K | Put options by funds: $266K

40% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 25

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

55% less capital inflows, than outflows

Capital inflows: $1.54M | Capital outflows: $3.41M

Holders
75
Holders Change
-3
Holders Change %
-3.85%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
15
Reduced
25
Closed
10
Calls
$226​K
Puts
$266​K
Net Calls
-⁠$40​K
Net Calls Change
-⁠$108​K

GALT Hedge Fund Activity: Q1 2021 in Review

75 of the 5,709 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2021, worth a combined $22.7M — down 5.2% from $24M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GALT and 5 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 15 added.

The largest buyer was Renaissance Technologies, adding an estimated $653K. The largest seller was D.A. Davidson & Co, cutting an estimated $1.57M.

  • 75 institutional investors held Galectin Therapeutics (GALT) as of Q1 2021, down from 78 in Q4 2020.
  • Funds reported $22.7M of Galectin Therapeutics stock for Q1 2021, down 5.2% quarter-over-quarter.
  • 5 funds opened new Galectin Therapeutics positions in Q1 2021 and 10 closed out, a net change of -5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $653K added.
  • The largest Galectin Therapeutics seller in Q1 2021 was D.A. Davidson & Co, an estimated $1.57M sold.

Based on aggregated 13F filings for Q1 2021.